Comparative Pharmacology
Head-to-head clinical analysis: CARDENE SR versus DILACOR XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE SR versus DILACOR XR.
CARDENE SR vs DILACOR XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nicardipine is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It produces relaxation of coronary vascular smooth muscle and dilation of coronary arteries, and also dilates peripheral arteries, reducing systemic vascular resistance and blood pressure.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Initial: 30 mg orally twice daily (SR capsules). Titrate up to 60 mg twice daily. Usual maintenance: 30-60 mg twice daily.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
None Documented
None Documented
Terminal elimination half-life 8.6 hours (range 6-15 hours). Clinical context: No accumulation at steady state with TID dosing.
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Renal: 60% (metabolites, unchanged drug <1%); Biliary/Fecal: 35%
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker